Download PDF
Semin Vasc Med 2003; 03(2): 193-198
DOI: 10.1055/s-2003-40677
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

The Role of the Tissue Factor-Thrombin Pathway in Cardiac Ischemia-Reperfusion Injury

Nigel Mackman
  • Departments of Immunology and Cell Biology, The Scripps Research Institute, La Jolla, CA
Further Information

Publication History

Publication Date:
18 July 2003 (online)

    Permissions and Reprints

ABSTRACT

This article focuses on the role of the tissue factor (TF)-thrombin pathway in cardiac ischemia-reperfusion (I/R) injury. We and others have used rabbit models of cardiac I/R injury to show that anti-TF therapy prevents the transient decrease in regional myocardial blood flow, reduces platelet and fibrin(ogen) accumulation, and reduces infarct size. At present, the mechanism by which TF-initiated coagulation contributes to myocardial injury is not established. Inhibition of TF may decrease intravascular fibrin deposition and thrombosis. However, immunohistochemical studies demonstrated that fibrin deposition was predominantly within the myocardium and depletion of fibrinogen did not reduce infarct size. In contrast, inhibition of thrombin reduced infarct size to a similar extent as anti-TF therapy. We propose that the TF-thrombin pathway may contribute to myocardial injury by an additional mechanism that is not dependent on fibrin deposition but involves activation of protease activated receptor 1 (PAR-1) on vascular endothelial cells and cardiac myocytes. Anti-TF therapy would inhibit both thrombin-dependent fibrin deposition and thrombin-dependent PAR-1 signaling.

KEYWORDS

Cardiac ischemia-reperfusion injury - tissue factor - coagulation - protease activated receptor

REFERENCES

  • 1 Bolli R. Oxygen-derived free radicals and myocardial reperfusion injury: an overview.  Cardiovasc Drugs Ther . 1991;  5 249-268
    CrossrefPubMedGoogle Scholar
  • 2 Homeister J W, Satoh P, Kilgore K S, Luchessi B R. Effects of complement activation in the isolated heart. Role of the terminal complement components.  Circ Res . 1992;  71 303-319
    PubMedGoogle Scholar
  • 3 Entman M L, Smith W C. Postreperfusion inflammation: a model for reaction to injury.  Cardiovasc Dis . 1994;  28 1301-1311
    PubMedGoogle Scholar
  • 4 Jordan J E, Zhao Z Q, Vinten-Johansen J. The role of neutrophils in myocardial ischemia-reperfusion injury.  Cardiovasc Res . 1999;  43 860-878
    CrossrefPubMedGoogle Scholar
  • 5 Entman M L, Michael L, Rossen R D. Inflammation in the course of early myocardial ischemia.  FASEB J . 1991;  5 2529-2537
    PubMedGoogle Scholar
  • 6 Herskowitz A, Choi S, Ansari A A, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium.  Am J Pathol . 1995;  146(2) 419-428
    PubMedGoogle Scholar
  • 7 Matsumura K, Jeremy R W, Schaper J, Becker L C. Progression of myocardial necrosis during reperfusion of ischemic myocardium.  Circulation . 1998;  97 795-804
    PubMedGoogle Scholar
  • 8 Ma X L, Lefer D J, Lefer A M, Rothlein R. Coronary endothelial and cardiac protective effects of a monoclonal antibody to intercellular adhesion molecule-1 in myocardial ischemia and reperfusion.  Circulation . 1992;  86(3) 937-946
    PubMedGoogle Scholar
  • 9 Ma X L, Tsao P S, Lefer A M. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion.  J Clin Invest . 1991;  88(4) 1237-1243
    PubMedGoogle Scholar
  • 10 Boyle Jr M E, Kovacich J C, Hébert C A. inhibition of interleukin-8 blocks myocardial ischemia-reperfusion injury.  J Thorac Cardiovasc Surg . 1998;  116 114-121
    PubMedGoogle Scholar
  • 11 Harlan J M, Winn R K. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy.  Crit Care Med . 2002;  30 S214-S219
    PubMedGoogle Scholar
  • 12 Edgington T S, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor.  Thromb Haemost . 1991;  66 67-79
    PubMedGoogle Scholar
  • 13 Davie E W, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation.  Biochemistry . 1991;  30 10363-10370
    CrossrefPubMedGoogle Scholar
  • 14 Drake T A, Morrissey J H, Edgington T S. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis.  Am J Pathol . 1989;  134 1087-1097
    PubMedGoogle Scholar
  • 15 Fleck R A, Rao L VM, Rapaport S I, Varki N. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody.  Thromb Res . 1990;  57 765-781
    CrossrefPubMedGoogle Scholar
  • 16 Coughlin S R. Thrombin signalling and protease-activated receptors.  Nature . 2000;  407 258-264
    CrossrefPubMedGoogle Scholar
  • 17 Déry O, Corvera C U, Steinhoff M, Bunnett N W. Proteinase-activated receptors: novel mechanisms of signaling by serine proteases.  Am J Physiol . 1998;  274 C1429-C1452
    PubMedGoogle Scholar
  • 18 Golino P, Ragni M, Cirillo P. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion.  Nature Med . 1996;  2 35-40
    CrossrefPubMedGoogle Scholar
  • 19 Erlich J H, Boyle Jr M E, Labriola J. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation.  Am J Pathol . 2000;  157 1849-1862
    CrossrefPubMedGoogle Scholar
  • 20 Mrak R E, Murphy M L, Peng C F, Straub K D. Microvasculature sparing with controlled reperfusion of ischemic myocardium.  Am J Cardiovasc Pathol . 1990;  3 253-258
    PubMedGoogle Scholar
  • 21 Hui K Y, Haber E, Matsueda G R. Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen.  Science . 1983;  222 1129-1132
    PubMedGoogle Scholar
  • 22 Armaganian L, Kam G, Eisenberg P R, Schechtman K B, Abendschein D R. Role of tissue factor-mediated coagulation in ischemia/reperfusion-induced injury of Langendorf-perfused rabbit hearts.  Coron Artery Dis . 2000;  11 481-487
    CrossrefPubMedGoogle Scholar
  • 23 Golino P, Ragni M, Cirillo P. Recombinant human, active site-blocked factor VII reduces infarct size and the NO-reflow phenomenon in a rabbit model of myocardial ischemia and reperfusion.  Am J Physiol Heart Circ Physiol . 2000;  278 H1507-H1516
    PubMedGoogle Scholar
  • 24 Gertz S D, Fallon J T, Gallo R. Hirudin reduces tissue factor expression in neointima after balloon injury in rabbit femoral and porcine coronary arteries.  Circulation . 1998;  98 580-587
    PubMedGoogle Scholar
  • 25 Hatton M WC, Ross B, Soutward S MR, DeReske M, Richardson M. Pretreatment of rabbits with either hirudin, ancrod, or warfarin significantly reduces the immediate uptake of fibrinogen and platelets by the deendothelialized aorta wall after balloon-catheter injury in vivo.  Arterioscler Thromb Vasc Biol . 1998;  18 816-824
    PubMedGoogle Scholar
  • 26 Kupatt C, Habazettl H, Hanusch P. c7E3Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen. Implications for myocardial reperfusion injury.  Arterioscler Thromb Vasc Biol . 2000;  20 2226-2232
    PubMedGoogle Scholar
  • 27 Cunningham M A, Rondeau E, Chen X, Coughlin S R, Holdsworth S R, Tipping P G. Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis.  J Exp Med . 2000;  191 455-461
    CrossrefPubMedGoogle Scholar
  • 28 Broze Jr J G. Tissue factor pathway inhibitor.  Thromb Haemost . 1995;  74(1) 90-93
    PubMedGoogle Scholar
  • 29 Presta L, Sims P, Meng Y G. Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic.  Thromb Haemost . 2001;  85 379-389
    PubMedGoogle Scholar
  • 30 Kelley R F, Refino C J, O'Connell M P. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent.  Blood . 1997;  89 3219-3227
    PubMedGoogle Scholar
  • 31 Nicolaisen E M, Kristensen H, Kristensen A, Hedner U. Evaluation of potential antigenicity of active-site-inhibited recombinant human FVIIa (FFR-rFVIIa) in an immune-tolerant rat model.  Thromb Haemost . 2002;  87 836-839
    PubMedGoogle Scholar
  • 32 Lee A, Agnelli G, Buller H. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement.  Circulation . 2001;  104 74-78
    PubMedGoogle Scholar
  • 33 Jang I-K, Gold H K, Leinbach R C, Fallon J T, Collen D, Wilcox J N. Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis.  Arterioscler Thromb . 1992;  12 948-954
    PubMedGoogle Scholar
  • 34 Pawashe A B, Golino P, Ambrosio G. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries.  Circ Res . 1994;  74 56-63
    PubMedGoogle Scholar
  • 35 Ragni M, Cirillo P, Pascucci I. Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis.  Circulation . 1996;  93 1913-1918
    PubMedGoogle Scholar
  • 36 Jang Y, Guzman L A, Lincoff A M. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model.  Circulation . 1995;  92(10) 3041-3050
    PubMedGoogle Scholar
  • 37 Oltrona L, Speidel C M, Recchia D, Wickline S A, Eisenberg P R, Abendschein D R. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs.  Circulation . 1997;  96 646-652
    CrossrefPubMedGoogle Scholar
  • 38 Abraham E, Reinhart K, Svoboda P. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.  Crit Care Med . 2001;  29 2081-2089
    CrossrefPubMedGoogle Scholar